Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,775 total articles

ZenaTech Initiates Plans for a Ukraine Testing Facility for Drone Testing and Operational Validation of its Interceptor Defense Systems

ZenaTech Initiates Plans for a Ukraine Testing Facility for Drone Testing and Operational Validation of its Interceptor Defense Systems

ZenaTech, Inc. announced plans to build a drone testing facility and operational deployment in Ukraine, leveraging the active drone warfare environment for real-world validation of its Interceptor defense systems. This initiative complements ZenaTech's planned manufacturing facility in Ukraine, aimed at producing cost-effective counter-UAS platform…

DeFi Development Corp. Releases March 2026 Recap Highlighting Strategic Execution, Research Expansion, and SPS Growth

DeFi Development Corp. Releases March 2026 Recap Highlighting Strategic Execution, Research Expansion, and SPS Growth

DeFi Development Corp. (Nasdaq: DFDV) released its March 2026 recap detailing robust financial performance with +442% revenue growth in 2025, growth in its Solana-based Digital Asset Treasury platform, and acceleration in adoption of its liquid staking token dfdvSOL. The company expanded research on AI-driven demand for Solana, advanced its strateg…

Prairie Operating Co. Announces Agreement to Further Extend Series F Anniversary Warrant Issuance Date

Prairie Operating Co. Announces Agreement to Further Extend Series F Anniversary Warrant Issuance Date

Prairie Operating Co., a Houston-based independent energy company focused on oil and natural gas in the Denver-Julesburg Basin, announced an extension of the Series F Convertible Preferred Stock warrant issuance date from April 7 to April 9, 2026. This extension allows the parties additional time for ongoing discussions with no guarantee of a defin…

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

BioRestorative Therapies, a Nasdaq-listed regenerative medicine company, has formed a strategic collaboration with brand strategy firm 203 Creates to develop and commercialize a biocosmeceutical product portfolio. This partnership aims to create a strong brand identity and a global go-to-market strategy to launch BioRestorative's BioX™ platform, fe…

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

22nd Century Group, Inc. announced progress on its 100mm VLN® reduced nicotine cigarette, aiming to expand its unique FDA-authorized low nicotine combustible cigarette portfolio through additional PMTA submissions. The company plans a broad product range and licensing strategy to reach wider consumer preferences and increase retail penetration, rei…

JFB Construction Announces 32% Increase in 2025 Year End Revenues as Compared with 2024 Year End Revenues

JFB Construction Announces 32% Increase in 2025 Year End Revenues as Compared with 2024 Year End Revenues

JFB Construction Holdings announced a 32% increase in 2025 year-end revenues compared to 2024, driven by diverse construction projects. The company is merging with XTEND, a leader in AI-driven autonomous defense robotics, in a $1.5 billion transaction expected to close by Q2 2026. The combined entity, to be renamed XTEND AI Robotics and listed on N…

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

Corbus Pharmaceuticals announced broad agreement with the FDA on registration trial designs for CRB-701, their next-generation ADC targeting Nectin-4, enabling potential accelerated approval for second-line treatment of head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The company plans to initiate registrational studies in mid-202…

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences

Recursion (Nasdaq: RXRX), a clinical-stage TechBio company specializing in AI-driven drug discovery, announced its participation in the 25th Annual Needham Virtual Healthcare Conference and the Bank of America Health Care Conference in 2026. The company highlights its AI-native platform, Recursion OS, which integrates biology, chemistry, and clinic…

Fusion Fuel Announces Approximately $1.14 Million in New LPG Engineering Subcontracts Awarded to Al Shola Gas Across Multiple Projects in Dubai, UAE

Fusion Fuel Announces Approximately $1.14 Million in New LPG Engineering Subcontracts Awarded to Al Shola Gas Across Multiple Projects in Dubai, UAE

Fusion Fuel Green PLC, via its subsidiary Al Shola Gas, has been awarded approximately $1.14 million in new LPG engineering subcontracts for multiple residential and mixed-use developments in Dubai, including a flagship dual-tower project valued at $0.5 million. These contracts support installation and commissioning of centralized LPG systems acros…

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S announced the completion of the one-year extension phase of its phase 2 trial for EVX-01, a personalized cancer vaccine developed with its AI-Immunology platform targeting advanced melanoma. Early trial results show a 75% objective response rate with durable clinical benefits and strong immune activation, underpinning the vaccine’s pote…

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience, a clinical-stage biotech company, announced its upcoming presentation at the GLP-1-Based Therapeutics Summit. The company will showcase its development of nimacimab, a first-in-class, peripherally-restricted monoclonal antibody targeting the CB1 receptor to provide additive benefits to GLP-1 therapies for obesity and metabolic heal…

Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials

Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials

Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of AI-driven solutions designed to automate workflows, enhance oversight, and improve productivity in clinical trials. Built on the existing Xcellerate® platform, FIT provides near-real-time, persona-driven insights to sponsors, sites, and study teams, aiming to accelerate clinica…

Nurix Therapeutics to Participate in Upcoming Investor Conference

Nurix Therapeutics to Participate in Upcoming Investor Conference

Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced that CEO Arthur Sands will participate in a fireside chat at the upcoming Needham Virtual Healthcare Conference. The company highlighted its current clinical and preclinical pipeline, including collaborations with major p…

Golar LNG Limited – Q1 2026 results presentation

Golar LNG Limited – Q1 2026 results presentation

Golar LNG Limited announced it will release its first-quarter 2026 financial results before market open on May 20, 2026, hosting a simultaneous webcast presentation and conference call for investors and analysts. This event will provide detailed insights into the company's recent performance, with opportunities for sell-side analysts to ask questio…